Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
Mazdutide activates GLP-1 and glucagon . The combined activity is associated with weight reduction (via appetite suppression and energy expenditure) and improved glycaemic control in clinical-trial research.
02
Research applications
- Obesity clinical research (predominantly Chinese populations)
- Type 2 diabetes clinical research
- Dual- incretin pharmacology
- Glucagon- metabolic research
Evidence at a glance
What's behind this profile
3 citations · 2021–2025
- Human
- 3
Studies in human volunteers or patients (incl. early-phase trials).
Publication years
- 21
- 22
- 23
- 24
- 25
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 3 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity
2021
Ji L et al. · EClinicalMedicine
- Model
- Phase 1b randomised placebo-controlled multiple-ascending-dose trial in Chinese adults
- Sample
- n=36
Mazdutide was associated with body-weight reductions up to 6.4% with primarily gastrointestinal adverse events in the dose-escalation cohort.
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity
2022
Ji L et al. · EClinicalMedicine
- Model
- Phase 1b randomised placebo-controlled multiple-ascending-dose trial (higher doses)
- Sample
- n=24
Higher-dose mazdutide (9–10 mg) was associated with body-weight reductions up to 11.7% in the cohort of Chinese adults with overweight or obesity.
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
2025
Ji L et al. · New England Journal of Medicine
- Model
- Phase 3 double-blind placebo-controlled RCT in Chinese adults with obesity or overweight
- Sample
- n=610
Mazdutide was associated with dose-dependent body-weight reductions up to 14.01% versus placebo with favourable cardiometabolic effects in the Chinese-population trial.
Evidence caveats
- Regulatory status varies by jurisdiction. Mazdutide is conditionally approved in China but is not FDA-approved (US) or EMA-approved (EU) at the time of writing.
- All primary published trials enrolled Chinese populations; generalisability to non-Asian populations is not established in the cited literature.
04
Storage and handling
Approved product (in China) follows manufacturer cold-chain instructions. Research-grade material must be stored under controlled laboratory conditions per protocol.
- Approved product (in China) follows the manufacturer label.
- Research-grade material requires controlled laboratory storage and full batch traceability.
- Investigational outside the approved jurisdiction; clinical decisions require a qualified healthcare professional.